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Background—T-cell targeted peptide epitope tolerogens from grass pollen allergens may be 
useful in treating seasonal allergic rhinitis, but there is urgent need for optimisation of approaches 
from improved understanding of mechanism.
Objective—We sought to identify human leukocyte antigen (HLA)-DR1-restricted epitopes from 
the Timothy grass pollen allergen, Phleum pratense, and characterise T-cell immune regulation 
following intranasal administration of a single, immunodominant epitope.
Methods—T-cell epitopes within P pratense were identified using HLA-DR1 transgenic mice 
and tetramer-guided epitope mapping (TGEM) in HLA-DR1-positive individuals with grass 
allergy. An immunodominant epitope was tested in HLA-DR1 transgenics for impact on responses 
to whole Phl p5 b or peptide. Microarrays and quantitative PCR were used to characterise T-cell 
immunity.
Results—Peptide 26 ( p26) was identified in HLA-DR1 transgenic mice and by TGEM analysis 
of HLA-DR1-positive individuals with grass allergy. p26 shows promiscuous binding to a wide 
range of HLA class II alleles, making it of relevance across immunogenetically diverse patients. 
The epitope is conserved in rye and velvet grass, making it applicable across a spectrum of grass 
pollen allergy. Intranasal pretreatment of mice with p26 results in significantly reduced T-cell 
responses. Transcriptomic array analysis in mice showed T-cell regulation in the intranasal 
treatment group associated with increased expression of members of the Cbl-b and Itch E3 
ubiquitin ligase pathway.
Conclusions—We defined an immunodominant P pratense epitope, p26, with broad binding 
across multiple HLA class II alleles. Intranasal treatment of mice with p26 results in T-cell 
regulation to whole allergen, involving the Cbl-b and Itch regulatory pathway.
INTRODUCTION
Allergic rhinitis and asthma triggered by grass pollen is an important cause of morbidity.1 
Many patients with these conditions express dissatisfaction with pharmacotherapy. For these 
patients, specific grass pollen immunotherapy, given as crude extract either subcutaneously 
or sublingually, is effective and associated with long-term benefits persisting after treatment 
is discontinued.23 However, subcutaneous immunotherapy is associated with a risk of IgE-
mediated systemic side effects. Sublingual grass pollen vaccines, while safe, require large 
quantities of allergen daily, usually for several years.4
An alternative immunotherapy involves targeting allergen-specific T cells with peptides 
containing immunodominant epitopes. This approach has shown promise in cat56 and bee 
venom7 allergy and avoids the immediate reactions associated with IgE crosslinking that 
limit the amount of native allergen that can be given subcutaneously. We have shown, using 
a human leukocyte antigen (HLA)-DR1 transgenic model of allergic asthma, that treatment 
with a peptide derived from the cat allergen Fel d 1 inhibited allergic airway inflammation.8 
Data from patients who received the vaccine also suggested that T-cell responses were 
suppressed to epitopes that were not administered, through ‘linked suppression’. The 
Allervax trial using Fel d 1 peptides showed improved pulmonary function in patients with 
reduced baseline FEV1 and global evaluation of the subjects’ ability to tolerate cats 
demonstrated significant improvement.9 The recent trials with short-course Cat-PAD found 
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persisting improvement in the ocular and nasal components of rhinoconjunctivitis symptoms 
in allergic subjects.10
In comparison to cat and bee venom, grass pollen contains a relatively large number of 
major allergens.11 Furthermore, numerous isoallergen variants have been described within 
allergen families.12 The viability of peptide vaccines for grass allergy is therefore likely to 
depend on identifying a relatively limited selection of immunodominant epitopes and 
establishing the potential for these to induce regulatory responses extending to T cells 
specific for other epitopes within the same and other major allergens. The need is to define 
immunodominant T-cell epitopes within common allergens, basing design of therapeutics 
around epitopes widely recognised by different individuals through the ability to bind 
multiple HLA class II molecules.
We investigated the HLA-DR1-restricted CD4T-cell responses to a major group five 
Timothy grass pollen allergen in transgenic HLA-DR1 mice and HLA-DR1-positive donors 
with grass allergy. The work builds on previous studies in which efforts have been made to 
map pollen epitope/HLA class II patterns of immune recognition using ex vivo analysis of 
T-cell lines in allergic individuals.13–16 The novelty of our approach is in the combination of 
immunisation of HLA-DR1 transgenic mice to define immunodominance and 
characterisation of human responses by tetramer-guided epitope mapping (TGEM),1718 




Phleum pratense extract and purified natural Phl p 5b (nPhl p 5b) were supplied by ALK 
Abello (Horsholm, Denmark). Recombinant Phl p 5b (rPhl p 5b) was supplied by 
Allergopharma (Germany).1920 A Phl p 5b peptide library comprising 20-mer peptides 
overlapping by 12 amino acids was synthesised from the sequence of Phl p 5.0201 
(Proimmune, Oxford, UK) (table 1).
Recruitment and characterisation of study subjects
Subjects with a history of seasonal allergic rhinitis21 for a minimum of 2 years during the 
UK grass pollen season were recruited from the Royal Brompton Hospital Allergy Clinic or 
through advertisement (table 2). All subjects had skin prick tests to common inhalant 
allergens: Dermatophagoides pteronyssinus, 6-grass pollen mix, Timothy grass, Alternaria 
alternata, three tree mix, Betula verrucosa, cat dander, dog dander, horse dander, and 
mugwort in the presence of positive (histamine) and negative (diluent) controls (Soluprick, 
ALK Abello, Horsholm). Subjects showed sensitisation to Timothy grass (P pratense), 
evidenced by a positive skin test response (wheal diameter >3 mm larger than elicited by 
diluent control) and elevated P pratense specific IgE. Non-allergic controls were 
asymptomatic with negative skin prick tests to common aeroallergens including P pratense 
and normal levels of total and allergen-specific IgE. All subjects and controls were HLA-
DRB1*0101 positive. The study was approved by the Royal Brompton and Harefield NHS 
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Trust Ethics Committee (06/ Q0404/43) and informed written consent was obtained (table 
2).
Transgenic mice
HLA-DR1 (DRA*0101/DRB1*0101) Aβ° transgenic mice have been described 
previously22; 8–14-week-old mice were used. Animal procedures were approved by the UK 
Home Office. UK Home Office regulations for animal welfare, based on the Animals 
(Scientific Procedures) Act 1986, were strictly observed.
HLA-DR1-restricted T-cell responses to Phl p 5b protein and overlapping peptide panel
HLA-DR1-restricted T-cell lines were made against Phl p 5 protein. HLA-DR1-tg/Aβ° mice 
(n=6) were footpad immunised with 25 μg nPhl p 5b in Complete Freund’s Adjuvant (CFA). 
Popliteal draining lymph nodes (DLNs) were harvested at day 10 and T-cell lines generated 
through two restimulations against nPhl p 5 protein (25 μg/mL) in the presence of irradiated 
mouse splenocytes as antigen presenting cells; this was repeated on three occasions and 
representative data from one of these are shown. T-cell proliferation in response to nPhl p 5 
and 20-mer overlapping peptides (table 1) spanning Phl p 5b at 50 μg/mL were assessed by 
addition of 1 μCi/well3H-thymidine during the final 18 h of a 72 h culture. Data are 
presented as the mean from triplicate wells minus the mean from triplicate wells containing 
cells plus medium.
Tetramer-guided epitope mapping
TGEM1718 was used to identify epitopes within Phl p 5b. The 32 overlapping peptides in 
pools were used to stimulate T-cell cultures from two individuals with grass allergy (table 2, 
URM018, URM031). Cells were cultured with peptide pools for 14 days prior to tetramer 
staining. Purified soluble DRA1*0101/DRB1*0101 molecules were produced from 
Schneider cells and loaded with peptide pools to generate tetramers. Tetramer-positive 
cultures staining with these tetramers were restained using HLA-DR1 tetramers loaded with 
each peptide from the positive pool.
Isolation and culture of PBMCs for tetramer analysis
Freshly isolated peripheral blood mononuclear cells (PBMCs) from DRB1*0101-allergic 
subjects and controls were cultured at 2×106 cells/mL in RPMI-1640 (Invitrogen, Life 
Technologies, UK) containing, L-glutamine (Sigma, UK), penicillin/streptomycin (Sigma) 
and 10% human AB serum (PAA Laboratories GmbH, Pasching, Austria) with 20 μg/mL 
Phl p 5b peptide 26 (p26) for 14 days. Recombinant human interleukin (IL)-2 (1 ng/mL) was 
added at day 7 (Proleukin, Novartis, UK).
Purified soluble DRA1*0101/DRB1*0101 molecules were loaded to generate HLA-DR1 
tetramer with Phl p 5 p26 or an irrelevant peptide (Phl p 1, p26) as a control tetramer.
At day 14, T cells were stained with anti-CD3-FITC, anti-CD4-PE-Cy5 (BD Pharmingen, 
Oxford, UK), PE-conjugated-DRB1*0101 tetramers and analysed by flow cytometry. 
Cultured Tcells were incubated with 10 μg/mL tetramer at 37°C for 1 h and costained with 
anti-CD3-FITC and anti-CD4-PE-Cy5 (BD Pharmingen) for 30 min. Cells were gated on 
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live lymphocytes according to forward and side scatter and the CD3 CD4 positive 
population to detect the p26-specific T-cell population and data acquired on a FACSCalibur 
(BD Biosciences, Oxford, UK).
For ex vivo phenotyping of tetramer-positive PBMCs, cells were gated on the tetramer-
positive CD4 population, then analysed within this gate for expression of CD45RA (Clone 
L48, BD Pharmingen), CCR4 (Clone 205410, R&D Systems), CCR3 (Clone 61828.111, 
R&D Systems), CXCR1 (Clone 5A12 BD, Pharmingen), CCR5 (Clone 45523, R&D 
Systems), CXCR3 (Clone 49801, R&D Systems), CCR7 (Clone 3D12, eBiosciences), 
CD62L (Clone DREG-56, eBiosciences) and CD38 (Clone 240742, R&D Systems).
Peptide binding to HLA-DR and HLA-DQ molecules
HLA-DR and HLA-DQ molecules were purified from homozygous Epstein–Barr virus cell 
lines by affinity chromatography with L24323–25 (HLA-DR) and SPVL3 (HLA-DQ).2324 
Binding to HLA-DR and HLA-DQ was assessed by competitive ELISA,23–25 evaluating the 
peptide concentration preventing binding of 50% of the labelled peptide (IC50). Data were 
expressed as relative affinity: ratio of the half maximal inhibitory concentration (IC50) of the 
peptide to the IC50 of the reference peptide, which is a high binder to the HLA class II 
molecule. Unlabelled forms of the biotinylated peptides were used as reference peptides. 
Their sequences and IC50 values were: HA 306–318 (PKYVKQNTLKLAT) for 
DRB1*0101 (2 nM), DRB1*0401 (14 nM), DRB1*1101 (72 nM); YKL 
(AAYAAAKAAALAA) for DRB1*0701 (5 nM), A3 152–166 (EAEQLRAYLDGTGVE) 
for DRB1*1501 (41 nM), MT 2–16 (AKTIAYDEEARRGLE) for DRB1*0301 (71 nM), B1 
21– 36 (TERVRLVTRHIYNREE) for DRB1*1301 (46 nM), CTP 427–441 
(VHGFYNPAVSRIVEA) for DRB1*0901 (23 nM), TFR141–155 (TGTIKLLNENSYVPR) 
(363 nM) for DRB1*1202, TFR607–620 (LNLDYERYNSQLLS) for DRB1*1502 (4 nM), 
B7150–164 (LNEDLRSWTAADTAA) for DQ6 (DQA1*0103/ DQB1*0603) (37 nM) and 
DQB45–57 (ADVEVYRAVTPLGPPD) for DQ8 (DQA1*0301/DQB1*0302) (98 nM).
Intranasal peptide treatment and T-cell assays
HLA-DR1-tg/Aβ° mice (seven per group) were treated with intranasal phosphate-buffered 
saline (PBS) or Phl p 5 p26 (100 μg) in 20 μL on days 1, 2 and 3. On day 21 mice were 
footpad primed with 25 μg of whole rPhl p 5b protein, Phl p 5b p26, or whole rPhl p 1 
protein as an emulsion with CFA (Sigma-Aldrich, UK). At day 31, single-cell suspensions 
were prepared from DLNs. Cells were cultured in triplicate with doses of whole rPhl p 5b 
protein, p26, or whole rPhl p 1 protein for 3 days. 1 μCi/well of 3H-thymidine was added 18 
h before termination of 72 h cultures. Data are represented as the mean from triplicate wells 
minus the mean from triplicate wells containing cells plus medium without antigen.
Microarray and real-time PCR analysis
HLA-DR1-tg/Aβ° mice received intranasal challenge with PBS or rPhl p 5b p26 (100 μg) on 
days 1, 2 and 3. On day 21 mice were primed with 25 μg of p26/CFA. At day 31, DLN 
suspensions were established as cultures with p26 (50 μg/mL). At 72 h cells were harvested 
and lysed for RNA analysis. cDNA was synthesised from 700 ng RNA (RT2 First strand kit, 
Qiagen, UK) and sample quality assessed by Mouse RT2 RNA QC PCR Array 
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(PAMM-999A, Qiagen). cDNA samples were assayed by PCR array (RT2 Profiler PCR 
array, PAMM-074Z, Qiagen). Plates were run on a Stratagene Mx3000p RT PCR machine 
for 10 min at 95°C followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Data were 
analysed using Partek Genomics Suite V.6.6 and significance determined using analysis of 
variance.
For real-time PCR, cDNA was synthesised from 500 ng RNA using SuperScript III reverse 
transcriptase (Invitrogen, Life Technologies). Real-time PCR was carried out in 20 μL 
containing 0.5 μL cDNA, 10μL 2XTaqMan Universal PCR Master Mix (Applied 
Biosystems, USA) and gene-specific probe and primers (Applied Biosystems: transforming 
growth factor β (TGFβ) inducible early gene 1 (TIEG-1) Mm00449812_m1, Itch 
Mm00492683_m1, Cblb Mm01343092_m1, Egr3 Mm00516979_m1; Sigma: Foxp3 
Forward 5′-ATAGTTCCTTCCCAGAGTTCTTCC, Reverse 5′-
ATGGTAGATTTCATTGAGTGTCCTC, Probe 5′-[FAM] 
CACCTATGCCACCCTTATCCGATGG[TAM]). PCR reactions were run in triplicate and 
CT values obtained using a MX3000P real-time PCR machine (Stratagene, USA) 
normalising to glyceraldehyde-3-phosphate dehydrogenase. Student’s t test was used to 
determine significance between groups. Statistically significant differences were defined as 
p values of less than 0.05.
RESULTS
HLA-DR1 restricted T-cell response to a Phl p 5b peptide panel identifies immunodominant 
epitopes of Phl p 5b
Since most humans are heterozygous with respect to the HLA region and also will present 
peptide to CD4 T cells via multiple HLA class II isotypes, definition of common peptide–
major histocompatibility complex combinations can be challenging. We addressed this 
through a combination of HLA transgenic, HLA-binding studies, TGEM and patient T-cell 
responses. HLA-DR1-tg/Aβ° mice were immunised with nPhl p 5b and T-cell lines made 
against nPhl p 5b protein. T-cell responses of these lines were tested against 20-mer 
overlapping peptides encompassing the Phl p 5b sequence (table 1). Peptides p18, p23 and 
p26 together with whole allergen elicited strong T-cell responses (figure 1). p26 shows 
sequence conservation with allergens from other grass species, including rye grass and 
velvet grass, making it of applicability across a spectrum of grass pollen allergy (table 3).
Immunodominant epitopes of Phl p 5b bind diverse HLA class II alleles
Epitopes, p18, p23 and p26 were analysed for binding to common HLA-DR and DQ alleles 
(table 4). p26 is unusual in its ability to bind with moderate to high affinity to extremely 
diverse HLA class II sequences, irrespective of isotype with the exception of HLA-DQ8. 
Note, however, that HLA-DQ8 would generally be carried on an HLA-DR4 haplotype, so 
that these individuals could in any case present the peptide through HLA-DR. The epitope 
also binds HLA-DRB1*1502, the more common DR15 variant in Asian populations, 
suggesting that the relevance of the epitope would extend beyond Caucasian patients.
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TGEM confirms Phl p 5b p26 as an HLA-DR1-restricted T-cell epitope
Seven pools of peptides were used to stimulate CD4 T cells from two HLA-DR1-positive 
subjects with grass allergy (table 2, URM018, URM031). Twelve days later, cells were 
analysed using HLA-DR1 tetramers loaded with each peptide pool; representative data are 
shown from donor URM031. Cells stimulated with pool 6 (p26–29) gave positive staining, 
with a weaker signal for pool 5 (p21–25) (figure 2A). On day 14, HLA-DR1 tetramers 
loaded with individual tetramers from pool six were used to stain the cells, identifying HLA-
DR1-restricted p26 (pool 6) (figure 2B).
Phl p 5b p26 HLA-DR1 tetramer-positive populations identified individuals with grass 
allergy
HLA-DR1-restricted CD4 T-cell responses to p26 were examined in six of the subjects with 
grass allergy and eight subjects without grass allergy, described in table 2 (figure 3A,B). 
Subjects with grass allergy (n=6) showed higher numbers of HLA-DR1 p26 tetramer 
positive CD4 T cells than controls without allergy (n=8) (p<0.01).
To assess the phenotype of p26-reactive donor cells, PBMCs from subjects with allergy 
were labelled ex vivo with p26/DR1 tetramer and costained for CD4, CXCR1, CCR3, 
CCR4, CXCR5, CCR7, CD62L, CD38 and CD45RA (figure 4). Tetramer-positive cells are 
of an effector memory type: CD45RAl°, CD62Ll°, CCR4hi, CCR3hi. In line with this, patient 
responses to p26 encompass an IL-5 response, but no detectable interferon γ (data not 
shown).
Intranasal treatment of mice with Phl p 5b p26 results in reduced response to p26 and 
whole rPhl p 5b protein
Intranasal administration of p26 substantially reduces the subsequent T-cell response to 
immunogenic challenge with p26 (figure 5). Intranasal treatment with just p26 is sufficient 
to significantly reduce the recall response to immune challenge with whole protein (figure 
5C) or with p26 itself (figure 5D). The induction of immune regulation is antigen specific 
since intranasal administration of p26 has no effect on priming and challenge with another 
Timothy antigen, Phl p 1 (figure 5E).
Increased expression of regulatory genes and decreased expression of Th2 inflammatory 
genes in p26-induced immune regulation
We then explored the transcriptomic pathways underlying p26-induced immune regulation 
by cDNA microarray analysis of peptide re-stimulated DLN cultures from peptide-treated or 
control HLA-DR1 transgenics (figure 6). The heatmap shows key genes differentially 
expressed following in vitro p26 re-stimulation of DLN cells. Intranasal peptide treatment 
prevents the full development of effector function: il4, il2ra are not upregulated, nor are 
Cd40, Fas and FasL. This is accompanied by an increase in transcripts that define a more 
regulatory response, including upregulation of Jak3, Tgfb1, Cbl-b, Egr3 and Rnf128.2627 
The most highly upregulated transcript in the dataset, Itga-1 (CD49a), is the α 1 chain of 
VLA-1. It is likely to have a role in regulation of cell trafficking to sites of allergen 
exposure.
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Cbl-b and Itch are in a pathway mediating p26-induced T-cell regulation
Changes in regulation-associated transcripts were confirmed by quantitative PCR (qPCR) 
(figure 7). Transcriptional changes in Itch and Cbl-b were noteworthy since they are 
considered gatekeepers regulating a key peripheral tolerance pathway in the anergy and 
autoimmunity.2627 We therefore investigated further the transcriptional changes to these 
genes and other changes potentially feeding through this pathway into changes at the Foxp3 
promoter, including those to TIEG-1.27 Individual qPCR assays on DLN cells from p26-
treated mice confirmed significant upregulation of Cbl-b, Itch, TIEG-1, Egr-3 and Foxp3.
DISCUSSION
There may be therapeutic value in the wider use of allergen peptide immunotherapy to 
regulate CD4 T cells without the risk of IgE binding.28 Grass pollens encompass the large 
numbers of allergens and isoallergens, making it important to identify T-cell grass pollen 
epitopes conserved across diverse grass species as a step towards defining the minimal 
antigenic requirements for clinical tolerance to whole grass pollen. Previously, an HLA-
DR4-restricted epitope was identified in rye grass Lol p 1.29 Identification of T-cell reactive 
regions within group five allergens of P pratense has been performed using Phl p 5 Tcell 
clones.830 A drawback of the latter studies is that they included small numbers of subjects of 
various HLA-DR haplotypes. As a result it is not clear if and how the identified T-cell 
reactive regions can or should be extrapolated to larger subject populations.
Screening T-cell lines from Phl p 5b immunised mice, we identified responses to p18, p23 
and p26. Of these, p26 is conserved across diverse grass pollens, including rye grass and 
velvet grass. A US national survey of individuals on prevalence of 19 allergen-specific IgEs 
showed the response to rye grass to be the most common of allergens tested.31 While 
evidence exists to support the importance of Phl p 5, as we have used here, it is possible that 
group I are also clinically important and that mixed peptide cocktails may be used for 
therapy.
The reductionism of HLA class II transgenics to identify the presenting class II heterodimer 
with TGEM analysis of human PBMCs offers a powerful approach to epitope 
characterisation. Tetramers loaded with the individual peptide revealed a population 
responding to p26. Further comparison showed a difference in the number of p26 tetramer-
positive cells expanded in individuals with allergy compared with those without allergy. 
While this study was based on cells expanded in culture ex vivo, our directly ex vivo TGEM 
data on individuals with allergy suggests frequencies in the range 1/60 000–1/300 000 T 
cells (data not shown). Whereas it can be hard to generalise from analysis of CD4 epitopes 
in a limited sample of individuals to applicability in a large outbred population expressing 
diverse HLA class II alleles, we show that p26 is likely to be of broad relevance due to its 
ability to bind multiple HLA class II heterodimers. Sette and colleagues characterised 
antigen-dominant regions of Phl p antigens predicted to bind diverse HLA alleles, a 
prediction we confirm empirically.32
Our microarray analysis pinpoints pathways defining a transcriptomic signature of 
regulation. At the top of this cascade stand changes to the transcription factor Egr-3, 
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upregulated in peptide-treated mice. Overexpression of Egr-3 has been associated with 
upregulation of Cbl-b, inhibition of T-cell activation and consequent tolerance.33 
Conversely, Egr-3-null mice show downregulation of Cbl-b and are resistant to peptide-
induced tolerance. The E3 ligase, Itch, named for the itchy skin allergic phenotype with 
autoimmunity and interstitial lung disease in knockout mice, is a regulator of peripheral 
tolerance.27 Cbl-b, another ubiquitin ligase controlling tolerance, was also upregulated in 
this biosignature (figures 6 and 7). This ubiquitin ligase is proposed to impact on the 
immunity/anergy switch point at several levels through interactions with different target 
substrates. Itch-mediated ubiquitination re-routes PLC-γ1 and PKC-θ to the lysosome for 
degradation, with the effect of curtailing the immune synapse.34 In general, the enhanced re-
sorting and degradation of immune signalling proteins mediated by E3 ubiquitin ligases is 
thought to cause an inability to maintain an intact immune synapse in stimulated T cells. 
Furthermore, there may be a more direct effect on TGFβ-induced Foxp3 expression as Itch 
knockouts show impairment of this pathway, presumably via its targeting by 
monoubiquitination of TIEG-1.27 The resulting response is a discrete effector rather than 
null response, evidenced by upregulation of Jak-3, which associates with the common γ 
chain, γc, pairing with ligand-specific subunits to supply receptors for IL-2, IL-4, IL-7, IL-9, 
IL-15 and IL-21.35
Itga-1 (CD49a), the α 1 chain of VLA-1, was very highly upregulated in mice treated with 
intranasal p26. This is noteworthy as a gene expression profiling study of human T 
regulatory type 1 (Tr1) cells by the Roncarolo group pinpoints CD49b and LAG-3 
coexpression as a defining signature, allowing therapeutic Tr1 cells to be tracked in vivo.36
It should be tractable to use these approaches demonstrated here for high-throughput 
mapping of immunodominant epitopes from allergens and the design of optimal tolerogenic 
regimens. We acknowledge that the present article does not extend from exploring the 
mechanism of immune regulation to in vivo evaluation of therapeutic efficacy. Further 
studies will be needed to determine if it is possible to manipulate tolerance using therapeutic 
drug agonists of the E3 ubiquitin ligases, as under consideration in other settings including 
oncogenesis.3738
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What is the key question?
To identify important immunodominant epitopes from the Timothy grass pollen allergen, 
Phleum pratense, and study T cell immune regulation following intranasal treatment 
using a single immunodominant epitope.
What is the bottom line?
We describe an immunodominant Phleum pratense epitope, p26, with binding across 
multiple Human Leukocyte Antigen (HLA) class II alleles and sequence conservation 
with allergens from other grass species including rye grass and velvet grass making it an 
epitope of potential applicability across a spectrum of grass pollen allergy in the majority 
of individuals; intranasal treatment with this peptide results in T cell regulation to whole 
allergen mediated through the Cbl-b and Itch pathway.
Why read on?
This study exploits an approach combining HLA transgenic mice, tetramer guided 
epitope mapping, HLA binding studies and therapeutic studies in mice to define immune 
targets for the development of therapeutics in pollen allergy and identify a novel 
molecular pathway for the induced tolerance, offering the potential for additional future 
drug targets.
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Human leukocyte antigen (HLA)-DR1 restricted T-cell responses to Phl p 5b protein and Phl 
p 5b 20-mer overlapping peptide panel. HLA-DR1-restricted T-cell lines were made against 
nPhl p 5 protein. HLA-DR1-Tg/Aβ° mice (n=6) expressing human HLA-DR1 were 
immunised with nPhl p 5b emulsified in Complete Freund’s Adjuvant. Draining lymph node 
cells were harvested at day 10 and T-cell lines generated against Phl p 5 protein. T-cell 
responses of lines were assessed after 72 h in a 3H-thymidine incorporation assay against 
Phl p 5 protein and 20-mer overlapping peptides spanning Phl p 5b, each at 50 μg/mL. The 
y-axis indicates T-cell proliferation in response to peptide, measured in Δcpm of 3H-
thymidine incorporation (ie, the difference between the mean count from triplicate wells in 
the presence or absence of peptide). The x-axis indicates the identity of the tested Phl p 5b 
peptides that were assayed for the ability to elicit a T-cell response. This assay was repeated 
on three separate occasions. Epitopes p18, p23 and p26 were confirmed by priming with the 
specific peptides (data not shown).
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Tetramer-guided epitope mapping identifies peptide 26 (p26) as a human leukocyte antigen 
(HLA)-DR1-restricted CD4T-cell epitope of Phl p 5b. A panel of overlapping 20-mer 
peptides spanning Phl p 5b was synthesised. Peptides were divided into pools and loaded 
onto PE-conjugated HLA-DR1 tetramers. Isolated CD4 T cells were cultured with adherent 
cells in the presence of the pooled peptides for 7 days before adding interleukin 2. Between 
days 12 and 14 the cells were stained with anti-CD4 and the pooled peptide tetramers (A). 
Positive tetramer staining was identified by flow cytometry. Individual peptide tetramers 
were generated and staining repeated (B). In this representative example, positive labelling 
is seen with HLA-DR1 tetramers loaded with p26 of Phl p 5b in patient URM031.
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Phl p 5b peptide 26 (p26) human leukocyte antigen (HLA)-DR1 tetramer-positive 
populations in study participants with and without allergy. Whole peripheral blood 
mononuclear cells isolated from HLA-DR1-positive individuals with grass allergy and 
seasonal allergic rhinitis, and healthy controls without allergy were cultured with Phl p 5b 
p26. At day 14, cells were labelled with anti-CD3-FITC, anti-CD4-PE-Cy5 antibodies and 
PE-conjugated-HLA-DR1 tetramer loaded with p26 (A, top panel) or control tetramer 
loaded with irrelevant peptide (A, bottom panel) and analysed by flow cytometry. Cells were 
gated on live lymphocytes according to forward and side scatter and the CD3 CD4 positive 
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population to detect the p26-specific T-cell population. The percentage of p26 tetramer-
positive cells for subjects with and without allergy is shown (B). Statistical analysis was 
performed using the Mann– Whitney U test (bars indicate median values). Samples were 
processed during the grass pollen season, 2010 (subjects with allergy, n=6; healthy controls 
without allergy, n=8).
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Effector memory phenotype of Phl p 5 peptide 26 (p26) tetramer-positive CD4 T cells from 
subjects with allergy. Peripheral blood mononuclear cells isolated from subjects with allergy 
were labelled immediately ex vivo with Phl p 5b peptide 26 tetramer. This was followed by 
cell surface staining with FL-1 conjugated cell surface maker antibodies and an anti-
CD4PE-Cy5. The expression of a FL-1 conjugated cell surface maker antibody was 
compared on total CD4high and CD4 human leukocyte antigen (HLA)-DR1 Phl p 5 p26 
tetramer-positive cells from HLA-DR1-positive individuals with grass allergy. The 
reduction in mean fluorescence intensity for CD62L and CD45RA staining of tetramer-
positive cells is indicated in online supplementary figure S1. Statistical analysis was 
performed using a Wilcoxon signed rank test. Samples were processed during the grass 
pollen season, summer 2010.
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Intranasal treatment with peptide 26 (p26) results in reduced T-cell proliferation to rPhl p 5b 
and p26. (A, B) Mice were treated intranasally with phosphate-buffered saline (PBS, filled 
squares) or p26 (filled triangles) at days 1, 2 and 3 and footpad primed at day 21 with (C) 
rPhl p 5 protein (each group, n=7), (D) p26 (each group, n=7) or (E) whole Phl p 1 protein 
(each group, n=5). Draining lymph nodes were harvested at day 31 and 3Hthymidine 
incorporation measured for protein or peptide as shown. An unpaired t test was used to 
determine significant differences between groups. Statistically significant differences were 
defined as p values of less than 0.05 (*p<0.05).
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Intranasal treatment of peptide 26 (p26) is associated with increased expression of 
regulatory genes and decreased expression of T helper 2 inflammatory genes. Mice were 
treated intranasally with phosphate-buffered saline (PBS) (n=6) or p26 (n=6) before footpad 
immunisation and in vitro p26 stimulation of draining lymph node (DLN) cells. (A) A heat 
map shows the key genes differentially expressed following in vitro p26 stimulation of DLN 
cells where fold change is greater than ±1.4 with a p value of <0.05 by analysis of variance. 
(B) Fold change values and p values for each of these differentially expressed genes are 
shown.
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Intranasal treatment of peptide 26 (p26) results in increased expression of key targets in the 
Itch-Foxp3-transforming growth factor β inducible early gene 1 (TIEG-1) pathway. (A) Cbl-
b, (B) Itch, (C) TIEG-1, (D) Foxp3 and (E) Egr3 are upregulated in p26-treated (n=3) 
compared with phosphate-buffered saline (PBS)-treated (n=3) mouse draining lymph node 
cells by real-time PCR. Student’s t test was used to determine significant differences 
between groups. Statistically significant differences were defined as p values less than 0.05 
(*p<0.05, ***p<0.0005).
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Table 1
Amino acid sequence of Phl p 5b 20-mer overlapping peptide sequences used for epitope mapping studies

































Each peptide overlaps by 12 amino acids.
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Table 3
Sequence alignment of the in silico defined epitope sequence (YAVFEAALT) within Phl p 5b peptide 26 
(p26), from Phleum pratense and other commonly occurring grass species allergens in the UK
Grass allergen p26 epitope sequence Percentage sequence alignment
Phl p 5.0201 YAVFEAALT –
Dac g 5 isoallergen 2 YAVFEAALT 100
Dac g 5 isoallergen 1 YAVFEAALT 100
Dac g 5 YAVFEAALT 100
Lol p VA YAVFEAALT 100
Lol p 5C YAVFEAALT 100
Hol l 5.0201 YAVFEAALT 100
Hol l 5b FAVFKAALT 77
Poa p 5.0201 FAVFKAALT 77
Phl p 5.0101 YTVFETALK 66
Hol l 5.0101 YTVFETALK 66
Lol p 5.0101 YTVSETALK 55
The TEPITOPE-predicted HLA-DR1-restricted epitope within Phl p 5b-derived p26 (YAVFEAALT) was identified in other grass species. 
Sequences were aligned using the CLUSTAL 2.0.12 multiple sequence alignment programme available via the European Bioinformatics Institute 
server: (http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalw2). The Phl p isoallergen investigated in this study is shown in bold. 
The table highlights the percentage identity of the epitope sequences following calculation of pairwise sequence alignment scores when compared 
with Phl p 5.0201. Dac g, Dactylis glomerata; HLA, human leukocyte antigen; Hol l, Holcus lanatus; Lol p, Lolium perenne; Phl p, Phleum 
pratense; Poa p, Poa pratensis.
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